HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Investigating the pathways in primary practice leading to the diagnosis of central hypothyroidism.

AbstractAIM:
Clinical diagnosis of central hypothyroidism is not always obvious: patients may live for years with symptoms. Endocrinologists and biochemists have suggested that a first-line TSH strategy will lead to avoidable delays in diagnosis and treatment of patients with central hypothyroidism. In order to improve timely diagnosis, and thus decrease morbidity from a treatable disease, this study aimed to investigate the diagnostic journey of patients with central hypothyroidism in the Waikato region of New Zealand.
METHOD:
A retrospective convenience sample seeking note review and semi-structured interviews were carried out with 16 patients who had a diagnosis of central hypothyroidism that was not caused by pituitary surgery or radiotherapy to the pituitary or hypothalamus.
RESULTS:
Seventy-five percent of participants had tests performed in general practice with results suggesting either pituitary disease or that further investigation would be required. In 38% (6/16) of participants diagnosis was made by the general practitioner. Time to diagnosis ranged from 3 months to more than 12 months. Seven participants identified having 3-6 visits to their general practitioner and five participants made 6 to 12 visits to their general practitioner prior to diagnosis. Lethargy was the most common symptom in 94% of participants. This was followed by changes in skin texture and body hair distribution and texture in 75% of participants and headaches in 63% of participants.
CONCLUSION:
Due to the era during which these patients were diagnosed, we did not find that a delay in diagnosis was due to an absence of FT4 requests; which a first-line TSH strategy would imply. It is important to recognise that a normal TSH does not exclude central hypothyroidism. By raising awareness with general practitioners of pituitary disease, with potential for deficiency of other anterior pituitary hormones, would focus more specific questioning on related symptoms.
AuthorsVeronique Gibbons, Ross Lawrenson, Phillipa Sleigh, Tania Yarndley, John V Conaglen
JournalThe New Zealand medical journal (N Z Med J) Vol. 125 Issue 1364 Pg. 83-90 (Oct 26 2012) ISSN: 1175-8716 [Electronic] New Zealand
PMID23242401 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Thyrotropin
  • Thyroxine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Critical Pathways
  • Female
  • Follow-Up Studies
  • Humans
  • Hypothyroidism (diagnosis, drug therapy, etiology)
  • Male
  • Middle Aged
  • New Zealand
  • Pituitary Diseases (complications, diagnosis)
  • Primary Health Care (methods)
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Thyroid Function Tests
  • Thyrotropin (blood)
  • Thyroxine (therapeutic use)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: